Inhibition of PAI-1 shifts cardiomyocyte fate from senescence toward apoptosis and mitigates doxorubicin-induced cardiotoxicity
Open Access
- 1 January 2025
- journal article
- Published by Science Exploration Press in Geromedicine
- Vol. 2 (2) , 202521
Abstract
Aims: Doxorubicin (Dox) is an effective chemotherapeutic agent, but its clinical use is limited by cardiotoxicity. Cellular senescence contributes to Dox-induced cardiac dysfunction; however, the underlying molecular mechanism mediating the effect of senescence remains poorly understood. This study aimed to identify senescence-associated factors secreted from cardiomyocytes in Dox-treated hearts and define their functional significance in Dox-induced cardiotoxicity. Methods: Mice with cardiomyocyte-specific expression of the endoplasmic reticulum BioID secretome profiling system were used to identify Dox-induced secreted factors. Functional analyses were performed in neonatal rat ventricular myocytes (NRVMs). The effects of plasminogen activator inhibitor-1 (PAI-1) inhibition were evaluated in Dox-treated mice by assessing senescence markers, apoptotic responses, and cardiac structure and function. p21High-tdTomato reporter mice were used to examine the fate of senescent cardiomyocytes in vivo. Results: PAI-1 was identified as a major component of the senescence-associated secretory phenotype and was robustly upregulated in Dox-treated cardiomyocytes. In NRVMs, PAI-1 promoted senescence and maintained the senescent phenotype, in part by conferring resistance to apoptosis. Pharmacological inhibition of PAI-1 reduced senescence markers, enhanced apoptotic responses, and preserved cardiac structure and function in Dox-treated mice. Fate mapping analyses with p21High-tdTomato mice revealed that PAI-1 inhibition decreased the number of p21High senescent cardiomyocytes in Dox-treated hearts. Notably, PAI-1 inhibition did not attenuate Dox cytotoxicity in EO771 murine breast cancer cells. Conclusion: PAI-1 is a key mediator of Dox-induced cardiac dysfunction. PAI-1 inhibition shifts the fate of cardiomyocytes from senescence toward apoptosis and preserves cardiac structure and function without compromising the antitumor function of Dox, highlighting PAI-1 as a potential therapeutic target for chemotherapy-associated cardiotoxicity.Keywords
This publication has 32 references indexed in Scilit:
- A small molecule inhibitor of PAI-1 protects against doxorubicin-induced cellular senescenceOncotarget, 2016
- A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Nonmyocytes From the Adult Mouse HeartCirculation Research, 2016
- Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in miceNature Medicine, 2015
- Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2Nature Medicine, 2013
- TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cellsThrombosis Research, 2013
- A Novel Inhibitor of Plasminogen Activator Inhibitor-1 Provides Antithrombotic Benefits Devoid of Bleeding Effect in Nonhuman PrimatesJournal of Cerebral Blood Flow & Metabolism, 2010
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008
- Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damageAging Cell, 2007
- Increased Expression of Plasminogen Activator Inhibitor-1 in Cardiomyocytes Contributes to Cardiac Fibrosis after Myocardial InfarctionThe American Journal of Pathology, 2004
- p53 Phosphorylation at Serine 15 Is Required for Transcriptional Induction of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene by the Alkylating AgentN-Methyl-N′-nitro-N-nitrosoguanidineJournal of Biological Chemistry, 2001